J. Yuan and . M. Of-merck, Postow reports receiving honoraria from Bristol-Myers Squibb and Merck, and is a consultant/advisory board member for and reports receiving commercial research grants from

M. P. Squibb, Ascierto is a consultant/advisory board member for Amgen, Array, Bristol-Myers Squibb, MSD, Novartis, Roche-Genentech, and Ventana, and reports receiving commercial research grants from Bristol-Myers Squibb, Roche-Genentech, and Ventana. J.D. Wolchok is a consultant/advisory board member for and reports receiving commercial research grants from Bristol-Myers Squibb and Medimmune. G. Pawelec reports receiving speakers bureau honoraria from Astellas, Cellgene, Clasado, and Pfizer. C. Garbe is a consultant/advisory board member for Amgen, and reports receiving commercial research grants from Bristol-Myers Squibb, Novartis, and Roche, and speakers bureau honoraria and travel reimbursement from Amgen Weide reports receiving commercial research grants, honoraria, and travel support from Bristol-Myers Squibb. No potential conflicts of interest were disclosed by the other authors

A. Martens, J. D. Wolchok, G. Pawelec, B. W. Development, A. Martens et al., Weide Acquisition of data (provided animals, acquired and managed patients, provided facilities Weide Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis Weide Administrative, technical, or material support (i.e., reporting or organizing data, N Engl J Med, vol.363, pp.711-734, 2010.

C. Robert, L. Thomas, I. Bondarenko, O. Day, S. et al., Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, New England Journal of Medicine, vol.364, issue.26, pp.2517-2543, 2011.
DOI : 10.1056/NEJMoa1104621

D. Schadendorf, F. Hodi, C. Robert, J. Weber, K. Margolin et al., Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma, Journal of Clinical Oncology, vol.33, issue.17, pp.1889-94, 2015.
DOI : 10.1200/JCO.2014.56.2736

P. Sharma, K. Wagner, J. Wolchok, and J. Allison, Novel cancer immunotherapy agents with survival benefit: recent successes and next steps, Nature Reviews Cancer, vol.208, issue.11, pp.805-817, 2011.
DOI : 10.1038/nrc3153
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426440

C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski, A. Mackiewicz et al., Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib, New England Journal of Medicine, vol.372, issue.1, pp.30-39, 2015.
DOI : 10.1056/NEJMoa1412690

C. Robert, A. Ribas, J. Wolchok, F. Hodi, O. Hamid et al., Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial, The Lancet, vol.384, issue.9948, pp.1109-1126, 2014.
DOI : 10.1016/S0140-6736(14)60958-2

C. Meyer, L. Cagnon, C. Costa-nunes, P. Baumgaertner, N. Montandon et al., Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab, Cancer Immunology, Immunotherapy, vol.60, issue.10, pp.247-57, 2014.
DOI : 10.1007/s00262-013-1508-5

Y. Pico-de-coana, I. Poschke, G. Gentilcore, Y. Mao, M. Nystrom et al., Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production, Cancer Immunology Research, vol.1, issue.3, pp.158-62, 2013.
DOI : 10.1158/2326-6066.CIR-13-0016

S. Kitano, M. Postow, C. Ziegler, D. Kuk, K. Panageas et al., Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes, Cancer Immunology Research, vol.2, issue.8, pp.812-833, 2014.
DOI : 10.1158/2326-6066.CIR-14-0013

A. Tarhini, H. Edington, L. Butterfield, Y. Lin, Y. Shuai et al., Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab, PLoS ONE, vol.72, issue.2, p.87705, 2014.
DOI : 10.1371/journal.pone.0087705.s007

E. Simeone, G. Gentilcore, D. Giannarelli, A. Grimaldi, C. Caraco et al., Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma, Cancer Immunology, Immunotherapy, vol.60, issue.7, pp.675-83, 2014.
DOI : 10.1007/s00262-014-1545-8

J. Delyon, C. Mateus, D. Lefeuvre, E. Lanoy, L. Zitvogel et al., Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival, Annals of Oncology, vol.24, issue.6, pp.1697-703, 2013.
DOI : 10.1093/annonc/mdt027

G. Ku, J. Yuan, D. Page, S. Schroeder, K. Panageas et al., Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting, Cancer, vol.27, issue.22 pt 1, pp.1767-75, 2010.
DOI : 10.1002/cncr.24951

S. Wilgenhof, D. Four, S. Vandenbroucke, F. Everaert, H. Salmon et al., Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma, Journal of Immunotherapy, vol.36, issue.3, pp.215-237, 2013.
DOI : 10.1097/CJI.0b013e31828eed39

S. Kelderman, B. Heemskerk, H. Van-tinteren, R. Van-den-brom, G. Hospers et al., Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma, Cancer Immunology, Immunotherapy, vol.369, issue.2, pp.449-58, 2014.
DOI : 10.1007/s00262-014-1528-9

A. Sarnaik, Y. B. Yu, D. Morelli, D. Hall, M. Bogle et al., Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma, Clinical Cancer Research, vol.17, issue.4, pp.896-906, 2011.
DOI : 10.1158/1078-0432.CCR-10-2463

C. Gebhardt, A. Sevko, H. Jiang, R. Lichtenberger, M. Reith et al., Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab, Clinical Cancer Research, vol.21, issue.24, pp.5453-5462, 2015.
DOI : 10.1158/1078-0432.CCR-15-0676

D. Gabrilovich, S. Ostrand-rosenberg, and V. Bronte, Coordinated regulation of myeloid cells by tumours, Nature Reviews Immunology, vol.205, issue.4, pp.253-68, 2012.
DOI : 10.1038/nri3175

B. Weide, A. Martens, H. Zelba, C. Stutz, E. Derhovanessian et al., Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells, Clinical Cancer Research, vol.20, issue.6, pp.1601-1610, 2014.
DOI : 10.1158/1078-0432.CCR-13-2508

S. Walter, T. Weinschenk, A. Stenzl, R. Zdrojowy, A. Pluzanska et al., Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival, Nature Medicine, vol.174, issue.8, pp.1254-61, 2012.
DOI : 10.1016/j.cll.2007.05.002

R. Gabitass, N. Annels, D. Stocken, H. Pandha, and G. Middleton, Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with Surrogate Markers for Ipilimumab-Treated Patients www significant elevation of the Th2 cytokine interleukin-13, aacrjournals.org Clin Cancer Res Cancer Immunol Immunother, vol.2260, pp.1419-1449, 2011.

M. Miyara, Y. Yoshioka, A. Kitoh, T. Shima, K. Wing et al., Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor, Immunity, vol.30, issue.6, pp.899-911, 2009.
DOI : 10.1016/j.immuni.2009.03.019

W. Wang, D. Yu, A. Sarnaik, Y. B. Hall, M. Morelli et al., Biomarkers on melanoma patient T Cells associated with ipilimumab treatment, Journal of Translational Medicine, vol.10, issue.1, p.146, 2012.
DOI : 10.1002/eji.200939261

N. Tang, D. Shen, Y. Sun, J. Wen, S. Wolchok et al., Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy, Cancer Immunology Research, vol.1, issue.4, pp.229-263, 2013.
DOI : 10.1158/2326-6066.CIR-13-0020

D. Giacomo, A. Calabro, L. Danielli, R. Fonsatti, E. Bertocci et al., Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10??mg/kg within an expanded access programme, Cancer Immunology, Immunotherapy, vol.91, issue.Suppl 7, pp.1021-1029, 2013.
DOI : 10.1007/s00262-013-1418-6

A. Martens, K. Wistuba-hamprecht, M. Foppen, J. Yuan, M. Postow et al., Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab, Clinical Cancer Research, vol.22, issue.12, 2016.
DOI : 10.1158/1078-0432.CCR-15-2412
URL : https://hal.archives-ouvertes.fr/inserm-01409624

J. Wolchok, A. Hoos, O. Day, S. Weber, J. Hamid et al., Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clinical Cancer Research, vol.15, issue.23, pp.7412-7432, 2009.
DOI : 10.1158/1078-0432.CCR-09-1624

Y. Pico-de-coa~-na, M. Wolodarski, G. Gentilcore, Y. Yoshimoto, I. Poschke et al., Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation, Journal of Translational Medicine, vol.13, issue.Suppl 1, p.7, 2015.
DOI : 10.1186/1479-5876-13-S1-O7

J. Weber, O. Hamid, S. Chasalow, D. Wu, S. Parker et al., Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma, Journal of Immunotherapy, vol.35, issue.1, pp.89-97, 2012.
DOI : 10.1097/CJI.0b013e31823aa41c

P. Attia, G. Phan, A. Maker, M. Robinson, M. Quezado et al., Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti???Cytotoxic T-Lymphocyte Antigen-4, Journal of Clinical Oncology, vol.23, issue.25, pp.6043-53, 2005.
DOI : 10.1200/JCO.2005.06.205

M. Postow, S. Chasalow, J. Yuan, D. Kuk, K. Panageas et al., Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma, ASCO Meeting Abstracts, vol.31, p.9052, 2013.

J. Yuan, M. Adamow, B. Ginsberg, T. Rasalan, E. Ritter et al., Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab, Proceedings of the National Academy of Sciences, vol.108, issue.40, pp.16723-16731, 2011.
DOI : 10.1073/pnas.1110814108

J. Yuan, S. Gnjatic, H. Li, S. Powel, H. Gallardo et al., CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit, Proceedings of the National Academy of Sciences, vol.105, issue.51, pp.20410-20415, 2008.
DOI : 10.1073/pnas.0810114105

S. Ishigami, S. Natsugoe, K. Tokuda, A. Nakajo, C. X. Iwashige et al., Prognostic value of intratumoral natural killer cells in gastric carcinoma, Cancer, vol.88, issue.3, pp.577-83, 2000.
DOI : 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.3.CO;2-M

S. Coca, J. Perez-piqueras, D. Martinez, A. Colmenarejo, M. Saez et al., The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma, Cancer, vol.3, issue.12, pp.2320-2328, 1997.
DOI : 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P

F. Villegas, S. Coca, V. Villarrubia, R. Jimenez, M. Chillon et al., Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer, Lung Cancer, vol.35, issue.1, pp.23-31, 2002.
DOI : 10.1016/S0169-5002(01)00292-6

T. Frankel, W. Burns, J. Riley, R. Morgan, J. Davis et al., Identification and characterization of a tumor infiltrating CD56+/CD16??? NK cell subset with specificity for pancreatic and prostate cancer cell lines, Cancer Immunology, Immunotherapy, vol.214, issue.12, pp.1757-69, 2010.
DOI : 10.1007/s00262-010-0897-y

F. Kohlhapp, J. Broucek, T. Hughes, E. Huelsmann, J. Lusciks et al., NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade, Journal for ImmunoTherapy of Cancer, vol.14, issue.5, p.18, 2015.
DOI : 10.1186/s40425-015-0063-3

S. Laurent, P. Queirolo, S. Boero, S. Salvi, P. Piccioli et al., The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-?? production, Journal of Translational Medicine, vol.11, issue.1, p.108, 2013.
DOI : 10.1007/s00262-005-0668-3

E. Romano, M. Kusio-kobialka, P. Foukas, P. Baumgaertner, C. Meyer et al., Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients, Proceedings of the National Academy of Sciences, vol.112, issue.19, pp.6140-6145, 2015.
DOI : 10.1073/pnas.1417320112

D. Dilillo, K. Yanaba, and T. Tedder, B Cells Are Required for Optimal CD4+ and CD8+ T Cell Tumor Immunity: Therapeutic B Cell Depletion Enhances B16 Melanoma Growth in Mice, The Journal of Immunology, vol.184, issue.7, pp.4006-4022, 2010.
DOI : 10.4049/jimmunol.0903009

C. Liakou, A. Kamat, D. Tang, H. Chen, J. Sun et al., CTLA-4 blockade increases IFN??-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients, Proceedings of the National Academy of Sciences, vol.105, issue.39, pp.14987-92, 2008.
DOI : 10.1073/pnas.0806075105

P. Kvistborg, D. Philips, S. Kelderman, L. Hageman, C. Ottensmeier et al., Anti-CTLA-4 therapy broadens the melanoma-reactive CD8þ T cell response, Sci Transl Med, vol.6, pp.254-128, 2014.
DOI : 10.1126/scitranslmed.3008918

E. Van-allen, D. Miao, B. Schilling, S. Shukla, C. Blank et al., Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, vol.350, issue.6257, pp.207-218, 2015.
DOI : 10.1126/science.aad0095

A. Snyder, V. Makarov, T. Merghoub, J. Yuan, J. Zaretsky et al., Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma, New England Journal of Medicine, vol.371, issue.23, pp.2189-99, 2014.
DOI : 10.1056/NEJMoa1406498

C. Robert, J. Schachter, G. Long, A. Arance, J. Grob et al., Pembrolizumab versus Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.372, issue.26, pp.2521-2553, 2015.
DOI : 10.1056/NEJMoa1503093

J. Larkin, V. Chiarion-sileni, R. Gonzalez, J. Grob, C. Cowey et al., Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, New England Journal of Medicine, vol.373, issue.1, pp.23-34, 2015.
DOI : 10.1056/NEJMoa1504030
URL : http://www.zora.uzh.ch/113016/1/608_Larkin%20et%20al%20_NEJM%202015.pdf

A. Kotsakis, M. Harasymczuk, B. Schilling, V. Georgoulias, A. Argiris et al., Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples, Journal of Immunological Methods, vol.381, issue.1-2, pp.14-22, 2012.
DOI : 10.1016/j.jim.2012.04.004